New Vaccine for WNV Awaits Approval
A new West Nile virus (WNV) equine recombinant canarypox vaccine awaits USDA approval, and once available, could pave the way for a new generation of equine vaccines in the United States. Merial developed this Recombitek equine WNV technology, and assembled a group of researchers, clinicians, and private practitioners in New Orleans, La., on Nov. 19, 2003, to review WNV and the research behin
- Topics: Article
A new West Nile virus (WNV) equine recombinant canarypox vaccine awaits USDA approval, and once available, could pave the way for a new generation of equine vaccines in the United States. Merial developed this Recombitek equine WNV technology, and assembled a group of researchers, clinicians, and private practitioners in New Orleans, La., on Nov. 19, 2003, to review WNV and the research behind the technology.
The vaccine uses canarypox (which is innocuous to mammals) as a vector for introducing a tiny amount of WNV DNA to the animal’s cells to induce immunity. To learn more about the vaccine, see article #4798 at www.TheHorse.com.
TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.
Start your free account today!
Already have an account?
and continue reading.
